Related Experiment Videos
Thrombolysis and postinfarction ventricular septal rupture
Insights
Thrombolytic treatment, like streptokinase, can accelerate ventricular septal rupture after myocardial infarction. However, early surgical repair is still feasible and can lead to favorable patient outcomes.
Area of Science:
- Cardiology
- Cardiovascular Surgery
- Medical Research
Background:
- Postinfarction ventricular septal rupture is a rare but serious complication of acute myocardial infarction.
- Thrombolytic therapy is commonly used to treat acute myocardial infarction.
- The impact of thrombolysis on the timing and surgical management of ventricular septal rupture is not well understood.
Purpose of the Study:
- To investigate the relationship between thrombolytic treatment and the development of postinfarction ventricular septal rupture.
- To evaluate the outcomes of surgical repair in patients who received thrombolysis compared to those who did not.
Main Methods:
- Retrospective study of patients with postinfarction ventricular septal rupture undergoing surgical repair.
- Comparison of patient groups based on receipt of thrombolytic therapy (streptokinase).
- Analysis of time intervals between myocardial infarction, septal rupture, and surgical intervention, alongside mortality rates and functional outcomes.
Main Results:
- Patients receiving thrombolysis (streptokinase) experienced septal rupture at a median of 24 hours post-myocardial infarction, versus six days for non-thrombolysis patients.
- Surgical repair was performed as early as 12 hours after thrombolysis, with one such patient recovering uneventfully.
- The surgical mortality rate was higher in the streptokinase group (33%) compared to the non-streptokinase group (21%).
Conclusions:
- Thrombolytic therapy is associated with an accelerated timeline for the development of interventricular septal breakdown following acute myocardial infarction.
- Despite increased risk, early surgical repair of ventricular septal rupture after thrombolysis is possible and can achieve positive patient outcomes.
- Further research is warranted to optimize the management of ventricular septal rupture in patients treated with thrombolytic agents.
Abstract:
We studied all patients with postinfarction ventricular septal rupture referred to the Oxford Heart Centre for operation over a 4 1/2-year period. Twenty one women and 8 men were admitted to the Centre, 13 of whom had received streptokinase and 16 of whom had not. The median interval between symptomatic onset of myocardial infarction and the development of septal rupture was 24 hours for those treated by early thrombolysis (all streptokinase) and six days for those who were not. Of the 26 patients who underwent surgical repair, three were operated on less than 36 hours after streptokinase infusion, in one case within 12 hours of thrombolytic treatment. Macroscopic observation of the disintegrating myocardium showed muscle bundles dissected by blood rendered incoagulable by thrombolytic treatment, together with the histologic features of reperfusion injury. The overall surgical mortality rate for the streptokinase group was 33% and for the others 21%. The patient operated on within 12 hours of thrombolytic treatment recovered uneventfully. Six of seven surgical deaths were caused by left ventricular or biventricular failure and one by gastrointestinal hemorrhage. All survivors were in New York Heart Association classes II or III between 2 weeks and 4 1/2 years after operation. We conclude that thrombolysis leads to early breakdown of the interventricular septum after acute myocardial infarction but does not preclude early repair.